|
WO2020223299A1
|
|
Methods and compositions for treating cns injury
|
|
US2019314350A1
|
|
Methods of using sustained release aminopyridine compositions
|
|
CA3059180A1
|
|
Sustained release compositions of 4-aminopyridine
|
|
US2020108016A1
|
|
Sustained release compositions of 4-aminopyridine
|
|
EP3355865A1
|
|
Sustained release compositions of 4-aminopyridine
|
|
AU2016206267A1
|
|
Compositions and methods of using chondroitinase abci mutants
|
|
AU2016204464A1
|
|
Proteoglycan degrading mutants for treatment of cns
|
|
ZA201502178B
|
|
Use of a neuregulin to treat peripheral nerve injury
|
|
AU2015200220A1
|
|
Method for achieving desired glial growth factor 2 plasma levels
|
|
AU2014202390A1
|
|
Methods for detecting cardiac damage
|
|
US2016058743A1
|
|
Methods for treating sensorimotor impairments associated with certain types of stroke using aminopyridines
|
|
CA2904055A1
|
|
Therapeutic dosing of a neuregulin or a fragment thereof for treatment or prophylaxis of heart failure
|
|
AU2014200000A1
|
|
Compositions and methods of using chondroitinase abci mutants
|
|
WO2014093475A1
|
|
Methods for treating parkinson's disease using aminopyridines
|
|
WO2014028387A1
|
|
Methods for improving walking capacity in patients with multiple sclerosis using an aminopyridine
|
|
AU2013206188A1
|
|
Method, apparatus and software for identifying responders in a clinical environment
|
|
NZ741225A
|
|
Use of neuregulin to treat peripheral nerve injury
|
|
WO2013149163A1
|
|
Use of neuregulin to treat peripheral nerve injury
|
|
AU2013201097A1
|
|
Proteoglycan degrading mutants for treatment of cns
|
|
NZ726034A
|
|
Methods for treating an impairment in gait and/or balance in patients with multiple sclerosis using an aminopyridine
|
